Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children

被引:44
作者
Lapierre, V
Mahé, C
Aupérin, A
Stambouli, F
Oubouzar, N
Tramalloni, D
Benhamou, E
Tiberghien, P
Hartmann, O
机构
[1] INSERM, Unite E0199, UPRES EA 2284, Etab Francais Sang Bourgogne Franche Comte,U645,I, F-25020 Besancon, France
[2] Inst Gustave Roussy, Unite Med Transfus & Hemovigilance, Villejuif, France
[3] Inst Gustave Roussy, Serv Biostat & Epidemiol, Dept Sante Publ, Villejuif, France
[4] Inst Gustave Roussy, Dept Pediat, Unite Transplantat Med, Villejuif, France
关键词
platelet transfusion; ABO-incompatibility; hepatic veno-occlusive disease; autologous hematopoietic stem cell transplantation; children;
D O I
10.1097/01.tp.0000167758.63247.f4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hepatic veno-occlusive disease is a major limiting factor of high-dose chemotherapy in children. The cells lining the hepatic vascular endothelium express blood group A and/or B antigens according to the patient's blood group. We designed a study evaluating the impact of platelet concentrates containing ABO-incompatible plasma transfused to young children with a high risk of hepatic veno-occlusive disease. Methods. In all, 186 consecutive children (median age: 4 years, range: 0.75-17 years), treated with high-dose chemotherapy containing busulfan followed by hematopoietic stem cell transplantation for neuroblastoma (n=112) or brain tumor (n=74) between 1988 and 1998, were investigated. The main endpoint was the occurrence of hepatic veno-occlusive disease. Multivariate analysis was performed using a Cox's regression model with transfusion of platelet concentrates containing ABO-incompatible plasma as a time-dependent covariate. Results. We found that 73 out of 186 (39%) children developed hepatic veno-occlusive disease after transplantation. Multivariate analysis demonstrated that two factors significantly increased the risk of hepatic veno-occlusive disease occurrence: transfusion of platelet concentrates containing ABO-incompatible plasma (P=0.003) and use of melpha-lan in the conditioning regimen (P=0.006). Conversely, the number of platelet concentrates transfusions per week, child's age, weight, sex, and use of cyclophosphamide in the conditioning regimen had no effect. Conclusions. Transfusion of platelet concentrates containing ABO-incompatible plasma increases the risk of hepatic veno-occlusive disease in young children treated with a busulfan-containing regimen. Binding of A and/or B antigens expressed on the surface of hepatic endothelial cells may promote this complication. Transfusion of platelet concentrates containing ABO-incompatible plasma should be avoided in these children.
引用
收藏
页码:314 / 319
页数:6
相关论文
共 33 条
[1]  
ATTAL M, 1992, BLOOD, V79, P2834
[2]   VENOOCCLUSIVE DISEASE OF THE LIVER - DEVELOPMENT OF A MODEL FOR PREDICTING FATAL OUTCOME AFTER MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
ANDERSON, GL ;
MORI, M ;
HINDS, MS ;
SHULMAN, HM ;
MCDONALD, GB .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) :1729-1736
[3]  
Carreras E, 1998, BLOOD, V92, P3599
[4]   Should immunoglobulin therapy be used in allogeneic stem-cell transplantation?: A randomized, double-blind, dose effect, placebo-controlled, multicenter trial [J].
Cordonnier, C ;
Chevret, S ;
Legrand, M ;
Rafi, H ;
Dhédin, N ;
Lehmann, B ;
Bassompierre, F ;
Gluckman, E .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (01) :8-18
[5]   NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology [J].
Coze, C ;
Hartmann, O ;
Michon, J ;
Frappaz, D ;
Dusol, F ;
Rubie, H ;
Plouvier, E ;
Leverger, G ;
Bordigoni, P ;
Behar, C ;
Beck, D ;
Mechinaud, F ;
Bergeron, C ;
Plantaz, D ;
Otten, J ;
Zucker, JM ;
Philip, T ;
Bernard, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (12) :3433-3440
[6]   Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease) [J].
DeLeve, LD ;
Shulman, HM ;
McDonald, GB .
SEMINARS IN LIVER DISEASE, 2002, 22 (01) :27-41
[7]   Chemotherapy for unresectable and recurrent intramedullary glial tumors in children [J].
Doireau, V ;
Grill, J ;
Zerah, M ;
Lellouch-Tubiana, A ;
Couanet, D ;
Chastagner, P ;
Marchal, JC ;
Grignon, Y ;
Chouffai, Z ;
Kalifa, C .
BRITISH JOURNAL OF CANCER, 1999, 81 (05) :835-840
[8]   Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation - A randomized, double-blind, placebo-controlled trial [J].
Essell, JH ;
Schroeder, MT ;
Harman, GS ;
Halvorson, R ;
Lew, V ;
Callander, N ;
Snyder, M ;
Lewis, SK ;
Allerton, JP ;
Thompson, JM .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (12) :975-+
[9]   LIVER-TRANSPLANTATION ACROSS ABO BLOOD-GROUP BARRIERS [J].
GUGENHEIM, J ;
SAMUEL, D ;
REYNES, M ;
BISMUTH, H .
LANCET, 1990, 336 (8714) :519-523
[10]   Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation:: a multivariate analysis in 218 patients treated in a single institution [J].
Hartmann, O ;
Valteau-Couanet, D ;
Vassal, G ;
Lapierre, V ;
Brugières, L ;
Delgado, R ;
Couanet, D ;
Lumbroso, J ;
Benhamou, E .
BONE MARROW TRANSPLANTATION, 1999, 23 (08) :789-795